Skip to main content
. 2006 Apr 19;2006(2):CD005321. doi: 10.1002/14651858.CD005321.pub2

45. Clinical benefit table: Orthovisc. Continuous outcome measures (3).

Study Time Treatment Outcome N of Pts Baseline Mean End of Study Mean Absolute Benefit Relative Difference
Karatosun 2005a 1‐4 wk E: Orthovisc Pain during transfer activity 39 2.5 4.0 ‐1.1 (W) ‐42.3% (W)
    C: Hylan G‐F 0   40 2.6 4.2    
Karatosun 2005a 5‐13 wk E: Orthovisc Pain during transfer activity 39 2.5 4.5 0.5 (I) 19.25 (I)
    C: Hylan G‐F 20   34 2.6 4.1    
Karatosun 2005a 14‐26 wj E: Orthovisc Pain during transfer activity 37 2.5 3.9 0.2 (I) 7.7% (I)
    C: Hylan G‐F 20   34 2.6 3.8    
Karatosun 2005a 45‐52 wk E: Orthovisc Pain during transfer activity 30 2.5 4.3 0.3 (I) 11.5% (I)
    C: Hylan G‐F 20   32 2.6 4.1    
Karatosun 2005a 1‐4 wk E: Orthovisc Walking distance 39 5.4 8.7 1.7 (I) 20.5% (I)
    C: Hylan G‐F 20   40 8.3 9.9    
Karatosun 2005a 5‐13 wk E: Orthovisc Walking distance 39 5.4 9.2 2.0 (I) 24.2% (I)
    C: Hylan G‐F 20   34 8.3 10.1    
Karatosun 2005a 14‐26 wk E: Orthovisc Walking distance 37 5.4 9.1 2.0 (I) 24.2% (I)
    C: Hylan G‐F 20   34 8.3 10.0    
Karatosun 2005a 45‐52 wk E: Orthovisc Walking distance 30 5.4 9.6 2.3 (I) 27.7% (I)
    C: Hylan G‐F 20   32 8.3 10.2    
Karatosun 2005a 1‐4 wk E: Orthovisc Range of motion 39 113.0 123.0 3.8 (I) 3.3% (I)
    C: Hylan G‐F 20   40 114.4 120.6    
Karatosun 2005a 5‐13 wk E: Orthovisc Range of motion 39 113.0 121.9 2.3 (I) 2.0% (I)
    C: Hylan G‐F 20   34 114.4 121.0    
Karatosun 2005a 14‐26 wk E: Orthovisc Range of motion 37 113.0 118.0 ‐0.4 (W) ‐0.3% (W)
    C: Hylan G‐F 20   34 114.4 119.8    
Karatosun 2005a 45‐52 wk E: Orthovisc Range of motion 30 113.0 122.0 2.1 (I) 1.8% (I)
    C: Hylan G‐F 20   32 114.4 121.3    
Atamaz 2005 1‐4 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 9.3 0 0%
    C: Hylan G‐F 20   20 12.4 8.3    
Atamaz 2005 5‐13 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 11.2 1.5 (W) 12.1% (W)
    C: Hylan G‐F 20   20 12.4 8.7    
Atamaz 2005 14‐26 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 11.9 0.5 (W) 4.0% (W)
    C: Hylan G‐F 20   20 12.4 10.4    
Atamaz 2005 36 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 10.4 ‐1.0 (I) 8.1% (I)
    C: Hylan G‐F 20   20 12.4 10.4    
Atamaz 2005 45‐52 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 11.2 0 0%
    C: Hylan G‐F 20   20 12.4 10.2    
Atamaz 2005 1‐4 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 42.9 ‐6.4 (I) ‐7.5% (I)
    C: Hylan G‐F 20   20 85.0 64.0    
Atamaz 2005 5‐13 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 58.4 27.6 (W) 32.5% (W)
    C: Hylan G‐F 20   20 85.0 45.5    
Atamaz 2005 14‐26 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 66.2 30.2 (W) 35.5% (W)
    C: Hylan G‐F 20   20 85.0 50.7    
Atamaz 2005 36 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 52.2 15.2 (W) 17.9% (W)
    C: Hylan G‐F 20   20 85.0 51.7    
Atamaz 2005 45‐52 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 56.7 22.4 (W) 26.4% (W)
    C: Hylan G‐F 20   20 85.0 49.0    
Atamaz 2005 1‐4 wk E: Orthovisc SF‐36 pain 20 36.4 47.5 ‐22.7 (W) ‐88.7% (W)
    C: Hylan G‐F 20   20 25.6 59.4    
Atamaz 2005 5‐13 wk E: Orthovisc SF‐36 pain 20 36.4 28.0 24.8 (W) 96.9% (W)
    C: Hylan G‐F 20   20 25.6 58.8    
Atamaz 2005 14‐26 wk E: Orthovisc SF‐36 pain 20 36.4 35.9 29.6 (W) 115.6% (W)
    C: Hylan G‐F 20   20 25.6 55.7    
Atamaz 2005 36 wk E: Orthovisc SF‐36 pain 20 36.4 45.3 9.3 (W) 36.3% (W)
    C: Hylan G‐F 20   20 25.6 43.8    
Atamaz 2005 45‐52 wk E: Orthovisc SF‐36 pain 20 36.4 37.7 19.8 (W) 77.3% (W)
    C: Hylan G‐F 20   20 25.6 46.7    
Atamaz 2005 1‐4 wk E: Orthovisc WOMAC physical function 20 41.5 35.2 11.9 (W) 20.4% (W)
    C: Hylan G‐F 20   20 58.3 40.1    
Atamaz 2005 5‐13 wk E: Orthovisc WOMAC physical function 20 41.5 36.2 11.3 (W) 19.4% (W)
    C: Hylan G‐F 20   20 58.3 41.7    
Atamaz 2005 14‐26 wk E: Orthovisc WOMAC physical function 20 41.5 41.8 16.1 (W) 27.6% (W)
    C: Hylan G‐F 20   20 58.3 41.9    
Atamaz 2005 36 wk E: Orthovisc WOMAC physical function 20 41.5 39.6 17.8 (W) 30.5% (W)
    C: Hylan G‐F 20   20 58.3 38.6    
Atamaz 2005 45‐52 wk E: Orthovisc WOMAC physical function 20 41.5 37.6 15.5 (W) 26.6% (W)
    C: Hylan G‐F 20   20 58.3 38.9    
Atamaz 2005 1‐4 wk E: Orthovisc SF‐36 physical functioning 20 44.5 54.2 ‐12.0 (W) ‐33.8% (W)
    C: Hylan G‐F 20   20 35.5 57.2    
Atamaz 2005 5‐13 wk E: Orthovisc SF‐36 physical functioning 20 44.5 41.5 ‐23.2 (W) ‐65.4% (W)
    C: Hylan G‐F 20   20 35.5 61.7    
Atamaz 2005 14‐26 wk E: Orthovisc SF‐36 physical functionin 20 44.5 44.5 ‐20.2 (W) ‐56.9% (W)
    C: Hylan G‐F 20   20 35.5 55.7    
Atamaz 2005 36 wk E: Orthovisc SF‐36 physical functioning 20 44.5 49.2 ‐4.8 (W) ‐13.5% (W)
    C: Hylan G‐F 20   20 35.5 45.0    
Atamaz 2005 45‐52 wk E: Orthovisc SF‐36 physical functioning 20 44.5 31.0 ‐32.0 (W) ‐90.1% (W)
    C: Hylan G‐F 20   20 35.5 54.0    
Atamaz 2005 1‐4 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 9.3 ‐1.2 (I) ‐8.5% (I)
    C: Physical therapy   40 14.2 11.3    
Atamaz 2005 5‐13 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 11.2 0.2 (W) 1.4% (W)
    C: Physical therapy   40 14.2 11.8    
Atamaz 2005 14‐26 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 11.9 1.4 (W) 9.9% (W)
    C: Physical therapy   40 14.2 11.3    
Atamaz 2005 36 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 10.4 ‐1.1 (I) ‐7.7% (I)
    C: Physical therapy   40 14.2 12.3    
Atamaz 2005 45‐52 wk E: Orthovisc WOMAC pain (Likert) 20 13.4 11.2 ‐3.5 (I) ‐24.6% (I)
    C: Physical therapy   40 14.2 15.5    
Atamaz 2005 1‐4 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 42.9 ‐6.4 (I) ‐7.5% (I)
    C: Physical therapy   40 93.5 43.5    
Atamaz 2005 5‐13 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 58.4 22.4 (W) 26.4% (W)
    C: Physical therapy   40 93.5 49.5    
Atamaz 2005 14‐26 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 66.2 29.2 (W) 34.4% (W)
    C: Physical therapy   40 93.5 48.5    
Atamaz 2005 36 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 52.2 15.2 (W) 17.9% (W)
    C: Physical therapy   40 93.5 50.7    
Atamaz 2005 45‐52 wk E: Orthovisc Spontaneous pain (0‐100 mm VAS) 20 70.3 56.7 22.4 (W) 26.4% (W)
    C: Physical therapy   40 93.5 59.5